Position in DYN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$4,589,663
-$3,477,663 QoQ
Shares Held
253,153
-38.6% QoQ
Ownership
0.136%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DYN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Qube Research & Technologies Ltd holds $2,443,068,185 across 169 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
798,715 | $240,437,176 | |
| 2 | INSM |
INSMED Inc
|
1,682,334 | $179,370,451 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
221,607 | $138,180,828 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,454,496 | $122,254,613 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
426,336 | $104,354,262 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
659,678 | $87,559,060 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
1,443,230 | $81,989,896 | |
| 8 | RPRX |
Royalty Pharma plc
|
1,412,112 | $79,177,119 |
All Filings in DYN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,589,663 | 253,153 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $8,067,326 | 412,440 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $10,496,577 | 829,769 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,539,716 | 791,987 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $7,121,544 | 680,836 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $6,299,402 | 267,377 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $832,122 | 23,166 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $2,857,623 | 100,656 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $709,475 | 53,344 | Shares | Sole | 2024-02-13 | |
| 2023-03-31 | $204,203 | 17,726 | Shares | Sole | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||